Zanzalintinib

Exelixis reports $539.5M in total revenues, $478.1M from Cabozantinib in the U.S., GAAP EPS of $0.40, and non-GAAP EPS of $0.47. The company updates revenue guidance and announces a favorable patent ruling for Cabozantinib. A collaboration with Merck expands the Zanzalintinib development program. A conference call is scheduled for 5:00 PM Eastern Time.

Merck and Exelixis plan to collaborate on clinical trials combining Exelixis’ zanzalintinib with Merck’s Keytruda for HNSCC and Welireg for RCC, aiming to improve outcomes in these cancers.

Exelixis and MSD partner to evaluate combining zanzalintinib with KEYTRUDA in Phase III HNSCC trial and with WELIREG in Phase I/II and Phase III RCC trials. MSD provides KEYTRUDA for Exelixis-sponsored STELLAR-305 trial and co-funds RCC trials, while Exelixis retains commercial rights to zanzalintinib.

Exelixis and Merck announce clinical collaboration to evaluate zanzalintinib with KEYTRUDA in HNSCC and with WELIREG in RCC, aiming to address unmet needs. Exelixis retains global rights to zanzalintinib, while Merck supplies KEYTRUDA and funds part of the RCC trials.

Arcus Biosciences partners with AstraZeneca for a clinical trial to assess the safety and efficacy of combining casdatifan (HIF-2a inhibitor) and volrustomig (PD-1/CTLA-4 bispecific antibody) in clear cell renal cell carcinoma patients.

DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech and Merck. Promising drugs like Atezolizumab and ADI-270 are under various clinical trial phases, with recent FDA Fast Track designations for ADI-270 in metastatic RCC.

DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech, Allogene Therapeutics, and Merck & Co. Inc. Promising therapies such as Atezolizumab and ALLO-316 are under various clinical trial phases, with recent FDA Fast Track designations and IND approvals for novel drugs like ADI-270 and AB-2100.